{"pmid":32350235,"title":"Coronavirus Disease 2019 (COVID-19) Information for Cardiologists- Systematic Literature Review and Additional Analysis.","text":["Coronavirus Disease 2019 (COVID-19) Information for Cardiologists- Systematic Literature Review and Additional Analysis.","BACKGROUND: Despite the rapidly increasing attention being given to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, more commonly known as coronavirus disease 2019 (COVID-19), the relationship between cardiovascular disease and COVID-19 has not been fully described.Methods and Results:A systematic review was undertaken to summarize the important aspects of COVID-19 for cardiologists. Protection both for patients and healthcare providers, indication for treatments, collaboration with other departments and hospitals, and regular update of information are essentials to front COVID-19 patients. CONCLUSIONS: Because the chief manifestations of COVID-19 infection are respiratory and acute respiratory distress syndrome, cardiologists do not see infected patients directly. Cardiologists need to be better prepared regarding standard disinfection procedures, and be aware of the indications for extracorporeal membrane oxygenation and its use in the critical care setting.","Circ J","Sugimoto, Tadafumi","Mizuno, Atsushi","Kishi, Takuya","Ito, Naoya","Matsumoto, Chisa","Fukuda, Memori","Kagiyama, Nobuyuki","Shibata, Tatsuhiro","Ohmori, Takashi","Oishi, Shogo","Fuse, Jun","Kida, Keisuke","Kawai, Fujimi","Ishida, Mari","Sanada, Shoji","Komuro, Issei","Node, Koichi","32350235"],"abstract":["BACKGROUND: Despite the rapidly increasing attention being given to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, more commonly known as coronavirus disease 2019 (COVID-19), the relationship between cardiovascular disease and COVID-19 has not been fully described.Methods and Results:A systematic review was undertaken to summarize the important aspects of COVID-19 for cardiologists. Protection both for patients and healthcare providers, indication for treatments, collaboration with other departments and hospitals, and regular update of information are essentials to front COVID-19 patients. CONCLUSIONS: Because the chief manifestations of COVID-19 infection are respiratory and acute respiratory distress syndrome, cardiologists do not see infected patients directly. Cardiologists need to be better prepared regarding standard disinfection procedures, and be aware of the indications for extracorporeal membrane oxygenation and its use in the critical care setting."],"journal":"Circ J","authors":["Sugimoto, Tadafumi","Mizuno, Atsushi","Kishi, Takuya","Ito, Naoya","Matsumoto, Chisa","Fukuda, Memori","Kagiyama, Nobuyuki","Shibata, Tatsuhiro","Ohmori, Takashi","Oishi, Shogo","Fuse, Jun","Kida, Keisuke","Kawai, Fujimi","Ishida, Mari","Sanada, Shoji","Komuro, Issei","Node, Koichi"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350235","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1253/circj.CJ-20-0302","keywords":["covid-19","cardiologist","heart failure","infection","myocardial injury"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1666138495578537985,"score":9.490897,"similar":[{"pmid":32336069,"title":"What should a cardiologist know about coronavirus disease 2019?","text":["What should a cardiologist know about coronavirus disease 2019?","Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) is the cause of coronavirus disease 2019 (COVID19). The most common symptoms of COVID19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum Creactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and Ddimer concentrations (36%-46.4%). Among comorbidities in patients with COVID19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated Nterminal pro-Btype natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the lifethreatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID19 symptoms, possible clinical manifestations, complications, and recommended treatment.","Kardiol Pol","Slawinski, Grzegorz","Lewicka, Ewa","32336069"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) is the cause of coronavirus disease 2019 (COVID19). The most common symptoms of COVID19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum Creactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and Ddimer concentrations (36%-46.4%). Among comorbidities in patients with COVID19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated Nterminal pro-Btype natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the lifethreatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID19 symptoms, possible clinical manifestations, complications, and recommended treatment."],"journal":"Kardiol Pol","authors":["Slawinski, Grzegorz","Lewicka, Ewa"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32336069","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.33963/KP.15302","locations":["myalgia","fatigue","thrombocytopenia","Nterminal"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138494281449473,"score":210.09944},{"pmid":32433342,"title":"Cardiovascular Manifestation and Treatment in COVID-19.","text":["Cardiovascular Manifestation and Treatment in COVID-19.","The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China on December 12, 2019 to over 200 countries, caused 2310572 infected individuals and 158691 mortalities, updated on 2020/4/19. Many studies have published timely to help global health-care workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (e.g. hypertension, coronary disease, or cardiomyopathy), diabetes, chronic kidney disease...etc., have worse outcomes after covid-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support.","J Chin Med Assoc","Su, Yen-Bo","Kuo, Ming-Jen","Lin, Ting-Yu","Chien, Chian-Shiu","Yang, Yi-Ping","Chou, Shih-Jie","Leu, Hsin-Bang","32433342"],"abstract":["The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China on December 12, 2019 to over 200 countries, caused 2310572 infected individuals and 158691 mortalities, updated on 2020/4/19. Many studies have published timely to help global health-care workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (e.g. hypertension, coronary disease, or cardiomyopathy), diabetes, chronic kidney disease...etc., have worse outcomes after covid-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support."],"journal":"J Chin Med Assoc","authors":["Su, Yen-Bo","Kuo, Ming-Jen","Lin, Ting-Yu","Chien, Chian-Shiu","Yang, Yi-Ping","Chou, Shih-Jie","Leu, Hsin-Bang"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433342","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/JCMA.0000000000000352","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667342288197517314,"score":207.62935},{"pmid":32462497,"title":"Rapid guide to the management of cardiac patients during the COVID-19 pandemic in Egypt: \"a position statement of the Egyptian Society of Cardiology\".","text":["Rapid guide to the management of cardiac patients during the COVID-19 pandemic in Egypt: \"a position statement of the Egyptian Society of Cardiology\".","COVID-19 pandemic poses an enormous challenge to healthcare system in Egypt. This document is a position statement from the Egyptian Society of Cardiology. It aims to provide information to cardiovascular healthcare providers in Egypt to guarantee delivery of quality patient care and ensure adequate levels of protection against infection during the COVID-19 pandemic. Older patients and those with cardiovascular disease are at higher risk of mortality. The current situation requires unusual allocation of resources which may negatively impact the care of patients with cardiovascular disease. Cardiologists should be prepared in the COVID-19 pandemic. The challenge is in providing the best quality of care despite limited resources while keeping all medical staff as safe as possible. Consider deferring elective procedures whenever possible. All medical staff should undergo rigorous training on infection control and the use of high-quality personal protection equipment. Cardiologists should promote telemedicine in the outpatient setting, prioritize outpatient contacts, and avoid nosocomial dissemination of the virus to patients and healthcare providers. A much conservative approach for emergent cardiac patients is recommended, and invasive interventions are reserved for high risk hemodynamically unstable patients. During the pandemic, the most important principles of treatment should be controlling the spread of infection as the first priority, prompt assessment of patient risk, recommending conservative medical therapy rather than invasive interventions, and strict infection control measures to limit infection spread within the hospital and to healthcare workers.","Egypt Heart J","Shaheen, Sameh","Awwad, Omar","Shokry, Khalid","Abdel-Hamid, Magdy","El-Etriby, Adel","Hasan-Ali, Hsam","Shawky, Islam","Magdy, Ahmad","Nasr, Gamila","Kabil, Hamza","Elhadidy, Amr","Zaki, Mohamad","Hegab, Ahmad","32462497"],"abstract":["COVID-19 pandemic poses an enormous challenge to healthcare system in Egypt. This document is a position statement from the Egyptian Society of Cardiology. It aims to provide information to cardiovascular healthcare providers in Egypt to guarantee delivery of quality patient care and ensure adequate levels of protection against infection during the COVID-19 pandemic. Older patients and those with cardiovascular disease are at higher risk of mortality. The current situation requires unusual allocation of resources which may negatively impact the care of patients with cardiovascular disease. Cardiologists should be prepared in the COVID-19 pandemic. The challenge is in providing the best quality of care despite limited resources while keeping all medical staff as safe as possible. Consider deferring elective procedures whenever possible. All medical staff should undergo rigorous training on infection control and the use of high-quality personal protection equipment. Cardiologists should promote telemedicine in the outpatient setting, prioritize outpatient contacts, and avoid nosocomial dissemination of the virus to patients and healthcare providers. A much conservative approach for emergent cardiac patients is recommended, and invasive interventions are reserved for high risk hemodynamically unstable patients. During the pandemic, the most important principles of treatment should be controlling the spread of infection as the first priority, prompt assessment of patient risk, recommending conservative medical therapy rather than invasive interventions, and strict infection control measures to limit infection spread within the hospital and to healthcare workers."],"journal":"Egypt Heart J","authors":["Shaheen, Sameh","Awwad, Omar","Shokry, Khalid","Abdel-Hamid, Magdy","El-Etriby, Adel","Hasan-Ali, Hsam","Shawky, Islam","Magdy, Ahmad","Nasr, Gamila","Kabil, Hamza","Elhadidy, Amr","Zaki, Mohamad","Hegab, Ahmad"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462497","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1186/s43044-020-00061-5","keywords":["covid-19","cardiovascular disease","egypt","pandemic"],"locations":["Egypt","Egypt","Egypt"],"countries":["Egypt"],"countries_codes":["EGY|Egypt"],"topics":["Prevention"],"weight":1,"_version_":1668079521416347650,"score":188.94113},{"pmid":32376532,"pmcid":"PMC7086133","title":"[Consensus of Chinese experts on diagnosis and treatment processes of acute myocardial infarction in the context of prevention and control of COVID-19 (first edition)].","text":["[Consensus of Chinese experts on diagnosis and treatment processes of acute myocardial infarction in the context of prevention and control of COVID-19 (first edition)].","The SARS-CoV-2 epidemic starting in Wuhan in December, 2019 has spread rapidly throughout the nation. The control measures to contain the epidemic also produced influences on the transport and treatment process of patients with acute myocardial infarction (AMI), and adjustments in the management of the patients need to be made at this particular time. AMI is characterized by an acute onset with potentially fatal consequence, a short optimal treatment window, and frequent complications including respiratory infections and respiratory and circulatory failure, for which active on-site treatment is essential. To standardize the management and facilitate the diagnosis and treatment, we formulated the guidelines for the procedures and strategies for the diagnosis and treatment of AMI, which highlight 5 Key Principles, namely Nearby treatment, Safety protection, Priority of thrombolysis, Transport to designated hospitals, and Remote consultation. For AMI patients, different treatment strategies are selected based on the screening results of SARS-CoV-2, the time window of STEMI onset, and the vital signs of the patients. During this special period, the cardiologists, including the interventional physicians, should be fully aware of the indications and contraindications of thrombolysis. In the transport and treatment of AMI patients, the physicians should strictly observe the indications for patient transport with appropriate protective measurements of the medical staff.","Nan Fang Yi Ke Da Xue Xue Bao","Bu, Jun","Chen, Mao","Cheng, Xiaoshu","Dong, Yifei","Fang, Weiyi","Ge, Junbo","Gong, Yanjun","He, Ben","Huang, Lan","Huo, Yong","Jia, Shaobin","Jiang, Jun","Li, Yue","Li, Zhao","Liang, Chun","Liu, Xuebo","Liu, Zhenyu","Ma, Xiang","Ma, Yitong","Qian, Juying","Shen, Chengxing","Shen, Difei","Shen, Li","Shi, Ruizheng","Su, Xi","Sun, Yingxian","Tang, Yida","Wang, Jianan","Wu, Yue","Xiang, Dingcheng","Xu, Tongda","Xu, Yawei","Yang, Yuejin","Zeng, Hesong","Zhang, Cheng","Zhang, Guogang","Zhang, Ruiyan","Zhang, Shuning","Zhang, Yun","Zhang, Zheng","Zheng, Bo","Zhou, Ning","32376532"],"abstract":["The SARS-CoV-2 epidemic starting in Wuhan in December, 2019 has spread rapidly throughout the nation. The control measures to contain the epidemic also produced influences on the transport and treatment process of patients with acute myocardial infarction (AMI), and adjustments in the management of the patients need to be made at this particular time. AMI is characterized by an acute onset with potentially fatal consequence, a short optimal treatment window, and frequent complications including respiratory infections and respiratory and circulatory failure, for which active on-site treatment is essential. To standardize the management and facilitate the diagnosis and treatment, we formulated the guidelines for the procedures and strategies for the diagnosis and treatment of AMI, which highlight 5 Key Principles, namely Nearby treatment, Safety protection, Priority of thrombolysis, Transport to designated hospitals, and Remote consultation. For AMI patients, different treatment strategies are selected based on the screening results of SARS-CoV-2, the time window of STEMI onset, and the vital signs of the patients. During this special period, the cardiologists, including the interventional physicians, should be fully aware of the indications and contraindications of thrombolysis. In the transport and treatment of AMI patients, the physicians should strictly observe the indications for patient transport with appropriate protective measurements of the medical staff."],"journal":"Nan Fang Yi Ke Da Xue Xue Bao","authors":["Bu, Jun","Chen, Mao","Cheng, Xiaoshu","Dong, Yifei","Fang, Weiyi","Ge, Junbo","Gong, Yanjun","He, Ben","Huang, Lan","Huo, Yong","Jia, Shaobin","Jiang, Jun","Li, Yue","Li, Zhao","Liang, Chun","Liu, Xuebo","Liu, Zhenyu","Ma, Xiang","Ma, Yitong","Qian, Juying","Shen, Chengxing","Shen, Difei","Shen, Li","Shi, Ruizheng","Su, Xi","Sun, Yingxian","Tang, Yida","Wang, Jianan","Wu, Yue","Xiang, Dingcheng","Xu, Tongda","Xu, Yawei","Yang, Yuejin","Zeng, Hesong","Zhang, Cheng","Zhang, Guogang","Zhang, Ruiyan","Zhang, Shuning","Zhang, Yun","Zhang, Zheng","Zheng, Bo","Zhou, Ning"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376532","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.12122/j.issn.1673-4254.2020.02.01","keywords":["myocardial infarction","novel coronavirus pneumonia","protection","thrombolysis","transshipment"],"locations":["Wuhan","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666596532337508352,"score":180.55911},{"pmid":32391719,"title":"Cardiovascular disease and COVID-19: les liaisons dangereuses.","text":["Cardiovascular disease and COVID-19: les liaisons dangereuses.","Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.","Eur J Prev Cardiol","Barison, Andrea","Aimo, Alberto","Castiglione, Vincenzo","Arzilli, Chiara","Lupon, Josep","Codina, Pau","Santiago-Vacas, Evelyn","Cediel, German","Emdin, Michele","Bayes-Genis, Antoni","32391719"],"abstract":["Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations."],"journal":"Eur J Prev Cardiol","authors":["Barison, Andrea","Aimo, Alberto","Castiglione, Vincenzo","Arzilli, Chiara","Lupon, Josep","Codina, Pau","Santiago-Vacas, Evelyn","Cediel, German","Emdin, Michele","Bayes-Genis, Antoni"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391719","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1177/2047487320924501","keywords":["covid-19","coronavirus","sars-cov-2","cardiovascular","comorbidities","risk factors"],"topics":["Treatment","Mechanism","Diagnosis","Prevention"],"weight":1,"_version_":1666528580179329024,"score":176.84604}]}